Fig. 2: Use of HDM/SCT and post-transplantation outcomes.
From: Race/ethnicity in systemic AL amyloidosis: perspectives on disease and outcome disparities
*Based on a subcohort of 1668 patients with available treatment data, of whom 765 received HDM/SCT. Differences in utilization were non-significant (P = 0.071). †Differences in hematologic complete response (hemCR) rates were also non-significant (P = 0.562). A multivariable logistic regression analysis of HDM/SCT utilization is provided. HDM/SCT high-dose melphalan and autologous stem cell transplantation, NHW non-Hispanic White, ref reference group, NHB non-Hispanic Black, NHO non-Hispanic other, OR odds ratio, BU Boston University, dFLC difference between involved and uninvolved free light chains.
